Stoke Therapeutics, Inc. (STOK) stock
STOKNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 6/30179% above fair value
$26.68+0.48 (+1.83%)
Close on Nov 13, 2026Market cap $1.72BP/E –Yield –
Stoke Therapeutics enterprise value
Enterprise value is market cap plus debt, minus cash: the value of the whole business to all its investors.
Stoke Therapeutics's enterprise value was $1.44B on Nov 11, 2026, against $1.46B a year earlier. Over the last 5 years it ranged from -$63.03M to $1.86B, with a median of $344.74M.
Enterprise Value at the end of each year
| Period | Period end | Value | Change |
|---|---|---|---|
| 2026 | Nov 11, 2026 | $1.44B | -4.1% |
| 2025 | Dec 31, 2025 | $1.50B | +335.5% |
| 2024 | Dec 31, 2024 | $344.74M | +1787.6% |
| 2023 | Dec 29, 2023 | $18.26M | -83.7% |
| 2022 | Dec 30, 2022 | $112.25M | -82.6% |
| 2021 | Dec 31, 2021 | $646.21M | -65.5% |
| 2020 | Dec 31, 2020 | $1.87B | +170.2% |
| 2019 | Dec 31, 2019 | $693.70M | – |
See a number that looks wrong?